ОСТРАЯ ПЕЧЕНОЧНАЯ НЕДОСТАТОЧНОСТЬ У ВЗРОСЛЫХ: ЭТИОЛОГИЯ, КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ, МЕТОДЫ КОРРЕКЦИИ
https://doi.org/10.20514/2226-6704-2017-7-3-171-180
Аннотация
В статье проведена систематизация информации об этиологии, эпидемиологии и клинических проявлениях острой печеночной недостаточности. Приведены статистические данные о частоте ее встречаемости при разных нозологических формах, описаны наиболее часто развивающиеся осложнения, изложены основные подходы к терапии. Цель обзора — улучшить осведомленность врачей об острой печеночной недостаточности.
Об авторах
С. П. Лукашик
УО «Белорусский государственный медицинский университет», кафедра инфекционных болезней, Минск
Беларусь
Беларусь
И. А. Карпов
УО «Белорусский государственный медицинский университет», кафедра инфекционных болезней, Минск
Беларусь
Беларусь
Список литературы
1. Acharya S.K., Bhatia V., Sreenivas V. et al. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology. 2009; 136: 2159-2168.
2. Agarwal K., Jones D.E., Burt A.D. et al. Metastatic breast carcinoma presenting as acute liver failure and portal hypertension, Am. J. Gastroenterol. 2002; 97: 750-751.
3. Alba L., Hay J.E., Angulo P. et al. Lactulose therapy in acute liver failure. J. Hepatol. 2002; 36: 33A.
4. Bernal W., Auzinger G., Dhawan A. et al. Acute liver failure. Lancet. 2010; 376: 190-201.
5. Bhatia V., Batra Y., Acharya S.K. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure — a controlled clinical trial. J. Hepatol. 2004; 41: 89-96.
6. Blei A.T., Olafsson S., Webster S. et al. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet. 1993; 341: 157-158.
7. Casals-Seoane F., Arberas-Dı´ez B., Garcı´a-Buey L. Tenofovir treatment of the severe acute hepatitis B. Rev. Esp. Enferm. Dig. 2013; 105(1): 57–58.
8. Chatauret N., Rose C., Therien G. et al. Mild hypothermia prevents cerebral edema and CSF lactate accumulation in acute liver failure. Metab. Brain Dis. 2001; 16: 95-102.
9. Dalton T.A., Berry R.S. Hepatotoxicity associated with sustained-release niacin . Am. J. Med. 1992; 93: 102-104.
10. Darwish M.S., Plessier A., Hernandez-Guerra M., Fet al. (European Netw ork for Vascular Disorders of the Liver). Etiology, management, and outcome of the Budd-Chiar i syndrome. Ann. Intern. Med. 2009; 151(3): 167.
11. Davies M.H., Mutimer D., Lowes J. et al. Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet. 1994; 343: 1 329-1330.
12. Drews R., Weinberger S. Thrombocytopenic disorders in critically ill patients. Am. J. Respir. Crit. Care Med. 2000; 162: 347-351.
13. Durwa rd Q.J., Amacher A.L., Del Maestro R.F. et al. Cerebral and cardiovascular responses to changes in head elevation in patients with intracranial hypertension. J . Neurosurg. 1983; 59: 938.
14. EASL Clinical Practice Guidelines: Wilson’s disease. J. Hepatol. 2012; 56(3): 671-685.
15. Ellis A., Wendon J. Circulatory, respiratory, cereb ral and renal derangements in acute liver failure: Pathophysiology and management. Semin. Liver Dis. 1996; 16: 379-3 87.
16. Ellis A.J., Wendon J.A., Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology. 2000; 32(3): 536-541.
17. Forbes A., Ale xander G.J., O’Grady J.G. et al. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology. 1989; 10; 306-310.
18. Fuhrmann V., Ager B., Zubkova A. et al. Hypoxic hepatitis — epidemiology, pathophysiologyand clinical manageme nt. Wien. Klin. Wochenschr. 2010; 122: 129-139. 1
19. Gazzard B.G., Henderson J.M., Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen p lasma therapy. Gut. 1975; 16(8): 617-620.
20. Hay J.E. Liver disease in pregnancy. A review . Hepatology. 2008; 47: 1067-1076.
21. Heckman K.D., Weiner G.J., Davis C.S. et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy f or adult leukemia; 10,000/mm3 versus 20,000/mm3. J. Clin. Oncol. 1997; 15: 1143-1149.
22. Hruby K., Csomos G., Fuhrmann M. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Human Toxicol. 1983; 2: 183-195.
23. Jain S., Pendyala P., Varma S. et al. Effect of renal dysfunction in fulminant hepatic failure. Trop. Gastroenterol. 2000; 21(3): 118-20.
24. Jalan R. , Damink S.W.M.O., Deutz N.E. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation fo r acute liver failure. Transplant. 2003; 75: 2034-2039.
25. Jochum C., Gieseler R.K., Gawlista I. Hepatitis B associated acute liver failure: immediate treatment with entecavir inhibits hepa titis B virus replication and potentially its sequelae. Digestion. 2009; 80: 235–240 . 2
26. Kamijo Y., Soma K., Nishida M. et al. Acute liver failure following intravenous methamphetamine. Vet. Hum. Toxicol. 2002; 44: 216-217.
27. Karvellas C.J., Cavazos J, Battenhouse H. et al. US Acute Liver Failure Study Gr oup Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure: a retrospective cohort study. Clin G astroenterol. Hepatol. 2014; 12(11): 1942.
28. Kaufmann P. Mushroom poisonings: syndromic diagnosis and treatment. Wien. Med. Wochenschr. 2007; 157: 493-502.
29. Keays R., Harrison P.M., Wendon J.A. A prospective controlled trial of intravenous N-acetylcysteine in paracetamol-induced fulminant hepatic failure. BMJ. 1991; 303: 1024-1029.
30. Larsen F.S., Hansen B.A., Ejler sen E. et al. Cerebral blood flow, oxygen metabolism and transcranial doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. Eur. J. Gastroenterol. Hepatol. 1996; 8: 261-265.
31. Lee W.M., Hyna n L.S., Rossaro L. et al. Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage no n-acetaminophen acute liver failure. Gastroenterology. 2009; 37(3): 856.
32. Lee W.M., Stravitz R.T., Larson A.M. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012; 55(3): 965-9 67.
33. Lee W.M., Squires R.H. Jr., Nyberg S.L. et al. Acute liver failure: Summary of a workshop. Hepatology. 2008 ; 47(4): 1401-1415.
34. Lisotti A., Eusebi L.H., Festi D. et al. Treatment with telbivudine for fulminant hepatitis B.J. Dig. Dis. 2013; 14(11): 619–621.
35. Lowenthal A., Tur-Kaspa R., Brower R.G. Acute liver failure complicating ductal breast carcinoma: two cases and literature review. Scand. J. Gastroenterol. 2003; 38: 1095-1096.
36. Manka P., Bechmann L.P., Coombes J.D. Hepatitis E virus infection as a possible c ause of acute liver failure in Europe. Clin. Gastroenterol. Hepatol. 2015; 13: 1836-1842.
37. Martin L.F., Booth F.V.M., Reines D. et al. Stress ulcers and organ failure in intubated patients in surgical intensive care units. Ann. Surg. 1992; 215: 332-337.
38. Montero J.L., Muntane J., de las Heras S. et al. Acute liver failure caused by hepatic melanoma infiltration. J. Hepatol. 2002; 37: 540-541.
39. Montanini S., Sinardi D. , Pratico C. Use of acetylsysteine as the life-saving antidote in Amanita phalloides (death cap) poisoning. Case report on 11 patie nts. Arzneimittelforschung. 1999; 49: 1044-1047.
40. Munoz S.J., Stravitz R.T., Gabriel D. Coagulopathy of acute liver failure. Clin. Li ver Dis. 2009; 13: 95-107.
41. Nath F., Galbraith S. The effect of mannitol on cerebral white matter water content. J. Neurosurg. 1986; 65:41-43.
42. Nielsen H.B., Tofteng F., Wang L.P. Cerebral oxygenation determined by near-infrared spectrophotometry in patients with fulminant hepatic failure. J. Hepatol. 2003; 38: 188-192.
43. O’Grady J.G., Portmann B ., Williams R. Fulminant hepatic failure. In: Diseases of the Liver, Schiff L, Schiff R (Eds), Lippincott, Philadelphia 1993.
44. Oketani M., Ido A., Tsubouchi H. Chan ging etiologies and outcomes of acute liver failure: A perspective from Japan. J. Gastroenterol. Hepatol. 2011; 26(1): 65-71.
45. Polson J., Lee M .W. AASLD Position Paper: The Management of Acute Liver Failure. Hepatol. 2005; 36: 1179-1197.
46. Rakela J., Mosley J.W., Edwards V.M. et al. A double-blind randomized trial of hydrocortisone in acute hepati c failure. Dig. Dis. Sci. 1991; 36: 1223-1228.
47. Roberts E.A., Schilsky M.L. AASLD Practice guidelines: A practi ce guideline on Wilson disease. Hepatol. 2003; 37: 1475-1492.
48. Rolando N., Gimson A., Wade J. et al. Prospective con trolled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology. 1993; 17: 196-201.
49. Rolando N., Wade J., Davalos M. et al. The sys temic inflammatory response syndrome in acute liver failure. Hepatology. 2000; 32: 734-739.
50. Ronan B.A., Agrwal N., Carey E.J. et al. Fulminant hepatit is due to human adenovirus. Infection. 2014; 42(1): 105-111.
51. Sato R.L., Wong J.J., Sumida S.M. Efficacy of superactivated charcoal administration late (3 hours) af ter acetaminophen overdose. Am. J. Emerg. Med. 2003; 21: 189-191.
52. Shami V.M., Caldwell S.H., Hespenheide E.E. e t al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003; 9: 138-143.
53. Sh erlock S. Diseases of the Liver and Biliary System — 12th edition / Ed By Dooley J., Look A.S.F., Burroughs A.K., Heathcote E.J., WILEY-BLACKWELL., 2011, 771.
54. Strauss G., Christiansen M., Moller K., Cleet al. S-100b and neuron-specific enolase in patients with fulminant hepatic falure. Liver Transpl, 2001; 7: 9 64-970.
55. Strauss G., Hansen B.A., Knudsen G.M. et al. Hyperventilation restores cerebral blood flow autoregulation in patients with acute l iver failure. J. Hepatol. 1998; 28: 199-203.
56. Tofteng F., Jorgensen L., Hansen B.A. et al. Cerebral microdialysis in pat ients with fulminant hepatic failure. Hepatol. 2002; 36: 1333-1340.
57. Vaquero J., Chung C., Cahill M.E. et al. Pathogenesis of hepatic encephalopathy in acute liver failu re. Semin. Liver Dis., 2003; 23: 259-269.
58. Woolf G.M., Petrovic L.M., Rojter S.E. et al. Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation. Dig. Dis. Sci . 1994; 391:1351-1358.
59. Yu J.W., Sun L.J., Zhao Y.H. et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig. Dis. Sci. 2010; 55: 775–783.
60. Yu J.W., Sun L.J., Yan B.Z. et al. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int. 2011; 31(4): 499–506
Рецензия
Для цитирования:
Лукашик С.П., Карпов И.А. ОСТРАЯ ПЕЧЕНОЧНАЯ НЕДОСТАТОЧНОСТЬ У ВЗРОСЛЫХ: ЭТИОЛОГИЯ, КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ, МЕТОДЫ КОРРЕКЦИИ. Архивъ внутренней медицины. 2017;7(3):171-180. https://doi.org/10.20514/2226-6704-2017-7-3-171-180
For citation:
Lukashyk S.P., Karpov I.A. ACUTE LIVER FAILURE IN ADULTS: ETIOLOGY, CLINICAL MANIFESTATIONS, METHODS OF CORRECTION. The Russian Archives of Internal Medicine. 2017;7(3):171-180. (In Russ.) https://doi.org/10.20514/2226-6704-2017-7-3-171-180
Просмотров:
1389
Послать статью по эл. почте 